Comment from Fargon, Inc.

Summary: Fagron Inc., a company providing pharmaceutical ingredients and services, requests that the FDA remove "glycosaminoglycans" from the 503A Category 1: Bulk Drug Substances Under Evaluation list. The company states that it no longer believes this substance meets the criteria for consideration as a bulk drug substance for compounding.